Literature DB >> 15653118

High mobility group box 1 (HMGB1) protein: possible amplification signal in the pathogenesis of falciparum malaria.

L M Alleva1, H Yang, K J Tracey, I A Clark.   

Abstract

High mobility group box 1 (HMGB1) protein, a DNA-binding protein that can also act as a pro-inflammatory cytokine if released from cells, is an important amplification signal in various forms of inflammation. The concentration of HMGB1 in serum taken at admission was increased in falciparum malaria in sixteen African children, more so in fatal cases than in those who subsequently recovered (P<0.001). Serum from both non-fatal (P=0.0048) and fatal (P<0.001) cases contained significantly more circulating HMGB1 than did serum from healthy Caucasian adults. These data provide an additional argument that malaria is fundamentally a systemic inflammatory state. In keeping with its developing role in sepsis, HMGB1 may enhance and prolong the inflammatory processes, and thus illness, in malaria.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15653118     DOI: 10.1016/j.trstmh.2004.06.008

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  14 in total

Review 1.  Thrombomodulin and its role in inflammation.

Authors:  Edward M Conway
Journal:  Semin Immunopathol       Date:  2011-07-31       Impact factor: 9.623

2.  Plasmodium falciparum-infected erythrocytes induce tissue factor expression in endothelial cells and support the assembly of multimolecular coagulation complexes.

Authors:  I M B Francischetti; K B Seydel; R Q Monteiro; R O Whitten; C R Erexson; A L L Noronha; G R Ostera; S B Kamiza; M E Molyneux; J M Ward; T E Taylor
Journal:  J Thromb Haemost       Date:  2006-09-26       Impact factor: 5.824

3.  Disruption of Parasite hmgb2 Gene Attenuates Plasmodium berghei ANKA Pathogenicity.

Authors:  Sylvie Briquet; Nadou Lawson-Hogban; Bertrand Boisson; Miguel P Soares; Roger Péronet; Leanna Smith; Robert Ménard; Michel Huerre; Salah Mécheri; Catherine Vaquero
Journal:  Infect Immun       Date:  2015-04-27       Impact factor: 3.441

Review 4.  High-mobility group box 1 (HMGB1) in childhood: from bench to bedside.

Authors:  Valeria Chirico; Antonio Lacquaniti; Vincenzo Salpietro; Caterina Munafò; Maria Pia Calabrò; Michele Buemi; Teresa Arrigo; Carmelo Salpietro
Journal:  Eur J Pediatr       Date:  2014-05-09       Impact factor: 3.183

5.  Elevated levels of high-mobility group box-1 (HMGB1) in patients with severe or uncomplicated Plasmodium falciparum malaria.

Authors:  Davide Angeletti; Mpungu Steven Kiwuwa; Justus Byarugaba; Fred Kironde; Mats Wahlgren
Journal:  Am J Trop Med Hyg       Date:  2013-02-11       Impact factor: 2.345

Review 6.  HMGB1 in health and disease.

Authors:  Rui Kang; Ruochan Chen; Qiuhong Zhang; Wen Hou; Sha Wu; Lizhi Cao; Jin Huang; Yan Yu; Xue-Gong Fan; Zhengwen Yan; Xiaofang Sun; Haichao Wang; Qingde Wang; Allan Tsung; Timothy R Billiar; Herbert J Zeh; Michael T Lotze; Daolin Tang
Journal:  Mol Aspects Med       Date:  2014-07-08

Review 7.  Blood coagulation, inflammation, and malaria.

Authors:  Ivo M B Francischetti; Karl B Seydel; Robson Q Monteiro
Journal:  Microcirculation       Date:  2008-02       Impact factor: 2.628

8.  Using Complementary and Alternative Medicines to Target the Host Response during Severe Influenza.

Authors:  Lisa M Alleva; Charles Cai; Ian A Clark
Journal:  Evid Based Complement Alternat Med       Date:  2009-09-24       Impact factor: 2.629

Review 9.  The RAGE axis in systemic inflammation, acute lung injury and myocardial dysfunction: an important therapeutic target?

Authors:  Benedict C Creagh-Brown; Gregory J Quinlan; Timothy W Evans; Anne Burke-Gaffney
Journal:  Intensive Care Med       Date:  2010-07-15       Impact factor: 17.440

10.  Systemic release of high mobility group box 1 (HMGB1) protein is associated with severe and fatal Plasmodium falciparum malaria.

Authors:  Sarah J Higgins; Katharine Xing; Hani Kim; Dylan C Kain; Feng Wang; Aggrey Dhabangi; Charles Musoke; Christine M Cserti-Gazdewich; Kevin J Tracey; Kevin C Kain; W Conrad Liles
Journal:  Malar J       Date:  2013-03-19       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.